natgillin/translations-raw huggingface dataset:
Approximately 80% of an orally administered dose of pirfenidone is cleared in the urine within 24 hours of dosing.
Približne 80 % perorálne podanej dávky pirfenidónu sa vylúči močom do 24 hodín po podaní dávky.
Approximately 80% of AR episodes occurred by Month 3 and were infrequent after Month 6.
Približne 80 % epizód AR sa vyskytlo do 3. mesiaca a boli vzácne po 6. mesiaci.
Approximately 80% of patients developed neutralizing antibodies capable of inhibiting the elosulfase alfa from binding to the cation- independent mannose-6-phosphate receptor.
Približne u 80 % pacientov sa vytvorili neutralizačné protilátky schopné inhibovať elosulfázu alfa z väzby na receptor manóza-6-fosfátu nezávislého od katiónov.
Approximately 80% of patients who received sodium oxybate during clinical trials maintained CNS stimulant use.
Približne 80 % pacientov, ktorí dostávali nátriumoxybát počas klinických štúdií, zotrvalo v užívaní CNS stimulancia.
Approximately 80% of the administered radioactivity was recovered in urine and 11% in the faeces.
Približne 80 % z podanej rádioaktivity sa zachytilo v moči a 11 % v stolici.
Approximately 80% of the dose was recovered in the urine and 15% in the faeces.
Približne 80 % dávky sa vylúčilo močom a 15 % stolicou.
Approximately 80% of the population were women, 87% Caucasian and 9% Black.
Približne 80 % bolo žien, 87 % belochov a 9 % černochov.
Approximately 82% of all patients in the trial had APACHE II (Acute Physiology and Chronic Health Evaluation II) scores of < 10 and 2.3% had bacteraemia at baseline.
Približne 82 % všetkých pacientov v skúšaní malo skóre APACHE II (Acute Physiology and Chronic Health Evaluation II) < 10 a 2,3 % pacientov malo východiskovú bakteriémiu.
Approximately 85% of patients receiving LEMTRADA tested positive for anti-alemtuzumab antibodies during the study, with 92% of these patients testing positive also for antibodies that inhibited LEMTRADA binding in vitro.
Približne 85 % pacientov, ktorým sa podávala LEMTRADA, malo počas štúdie pozitívny test na protilátky proti alemtuzumabu, pričom 92 % týchto pacientov malo pozitívny test aj na protilátky, ktoré inhibovali viazanie LEMTRADY in vitro.
Approximately 87% of patients had APACHE II scores of ≤ 10 and 4.0% had bacteraemia at baseline.
Na začiatku liečby malo približne 87 % pacientov skóre podľa škály APACHE II ≤ 10 a 4,0 % malo východiskovú bakteriémiu.
Approximately 88% of patients received concomitant ASA (range of 1 to 23 mg/kg/day).
Približne 88 % pacientov užívalo súčasne kyselinu acetylsalicylovú ASA (v rozmedzí od 1 do 23 mg/kg/deň).
Approximately 9% of patients can be expected to experience an adverse reaction.
Očakáva sa, že približne 9% pacientov môže zažiť nežiaduce účinky.
Approximately 9% of the total radioactivity was unassigned.
Približne 9 % celkovej rádioaktivity nebolo možné určiť.
Approximately 9-44% of the administered dose was found as unchanged riociguat in faeces.
Približne 9-44 % z podanej dávky sa zistilo ako nezmenený riociguát v stolici.
Approximately 90 % of an orally administered radiolabelled amprenavir dose was recovered in the urine and the faeces, primarily as amprenavir metabolites.
Približne 90% perorálne podanej dávky rádioaktívne označeného amprenaviru bolo vylúčené do moču a stolice, predovšetkým vo forme metabolitov amprenaviru.
Approximately 90% of 14C-labelled dose is excreted through the kidneys while less than 2% is found in the faeces.
Približne 90 % dávky označenej 14C sa vylúči obličkami a menej ako 2% sa nachádza v stolici.
Approximately 90% of 14C-labelled dose is excreted through the kidneys while less than 2% is found in the faeces.
Približne 90% 14C označenej dávky sa vylúči obličkami a menej ako 2% sa nachádzalo v stolici.
Approximately 90% of 14C-labelled dose is excreted through the kidneys while less than 2% is found in the faeces.
Približne 90% dávky označenej 14C sa vylúči obličkami a menej ako 2% sa nachádza v stolici.
Approximately 90% of circulating propranolol is bound to plasma proteins (albumin and alpha1 acid glycoprotein).
Približne 90 % cirkulujúceho propranololu sa viaže na plazmatické bielkoviny (albumín a alfa-1-kyslý glykoproteín).
Approximately 90% of spinosad is comprised of spinosyns A and D. Of that 90%, the ratio of spinosyn A to A+D is 0.85 when calculated as spinosyn A/spinosyn A+D. The consistency of this figure in pharmacokinetic and other studies indicates comparability in the absorption, metabolism and elimination of the two major spinosyns.
Približne 90 % spinosadu je zo spinosynov A a D. Z tých 90 % je pomer spinosynu A k A+D 0,85, keď sa počíta ako spinosyn A/spinosyn A+D. Konzistencia tohto čísla vo farmakokinetickej a iných štúdiách uvádza porovnateľnosť v absorpcii, metabolizme a eliminácii týchto dvoch veľkých spinosynov.
Approximately 90% of spinosad is comprised of spinosyns A and D. Of that 90%, the ratio of spinosyn A to A+D is 0.85 when calculated as spinosyn A/spinosyn A+D. The consistency of this figure in pharmacokinetic and other studies indicates comparability in the absorption, metabolism and elimination of the two major spinosyns.
Približne 90 % spinosadu pozostáva so spinozínov A a D. Z týchto 90 %, pomer výskytu spinozínu A ku A+D je 0,85 pri kalkulácii pomeru spinozínu A k spinozínu A+D. Konzistentnosť tejto hodnoty vo farmakokinetických a iných štúdiách vypovedá o porovnateľnosti v oblasti absorpcie, metabolizmu a eliminácie dvoch primárnych spinozínov.
Approximately 92 % of the dose is eliminated during ß-phase with a short elimination half-life of 30 minutes.
Približne 92 % dávky sa eliminuje počas - fázy s krátkym, 30-minútovým polčasom eliminácie.
Approximately 92% of the dose is eliminated during ß-phase with a short elimination half-life of 30 minutes.
Približne 92 % dávky sa eliminuje počas - fázy s krátkym, 30-minútovým polčasom eliminácie.
Approximately 93% of the patients had previously received antibiotic or immunosuppressive therapy.
Približne 93 % z týchto pacientov predtým dostalo antibiotickú alebo imunosupresívnu liečbu.
Approximately 95 % of the oral dose was absorbed.
Približne 95 % perorálnej dávky bolo absorbovaných.
Approximately 95 % of the oral dose was absorbed.
Približne 95% perorálnej dávky bolo absorbovaných.
Approximately 96-98% of midazolam is bound to plasma proteins.
Približne 96-98 % midazolamu sa viaže na plazmatické proteíny.
Approximately 97 % of meloxicam is bound to plasma proteins.
Približne 97 % meloxicamu sa viaže na plazmatické bielkoviny.
Approximately 97 % of meloxicam is bound to plasma proteins.
Približne 97 % meloxikamu je viazaných na proteíny plazmy.
Approximately 97 % of meloxicam is bound to plasma proteins.
Približne 97 % meloxikamu sa viaže na plazmatické bielkoviny.
Approximately 97 % of meloxicam is bound to plasma proteins.
Približne 97 % meloxikamu sa viaže na proteíny plazmy.
Approximately 97 % of meloxicam is bound to plasma proteins.
Približne 97% meloxicamu sa viaže na plazmatické bielkoviny.
Approximately 97 % of meloxicam is bound to plasma proteins.
Približne 97% meloxikamu je viazaných na proteíny plazmy.
Approximately 97 % of the administered dose was excreted in faeces and 83 % of that as unchanged orlistat.
Približne 97 % podanej dávky orlistatu sa vylúčilo stolicou, z čoho 83 % bolo v nezmenenej forme.
Approximately 97% of first-line patients experienced adverse reactions; the most commonly reported reactions in first line patients usually occurred in the first week of therapy.
Približne 97 % pacientov v prvej línii pociťovalo nežiaduce reakcie; najčastejšie hlásené reakcie sa u pacientov v prvej línii zvyčajne vyskytujú v priebehu prvého týždňa liečby.
Approximately 97% of meloxicam is bound to plasma proteins.
97 % av meloksikam er bundet til plasmaproteiner.
Approximately 97% of meloxicam is bound to plasma proteins.
Približne 97 % meloxikamu je viazaných na proteíny plazmy.
Approximately 97% of meloxicam is bound to plasma proteins.
Približne 97% meloxicamu sa viaže na plazmatické bielkoviny.
Approximately 97% of the administered dose was excreted in faeces and 83% of that as unchanged orlistat.
Približne 97 % podanej dávky orlistatu sa vylúčilo stolicou, z čoho 83 % bolo v nezmenenej forme.
Approximately 98 % of meloxicam is bound to plasma proteins.
Približne 98 % meloxikamu je viazaných na proteíny plazmy.
Approximately 98% of meloxicam is bound to plasma proteins.
Približne 98 % meloxikamu je viazaných na proteíny plazmy.
Approximately 98% of meloxicam is bound to plasma proteins.
Približne 98% meloxikamu sa viaže na plazmatické proteíny.
Approximately 98% of patients (in each of the treatment groups) received antithrombins (heparin, low molecular weight heparin, bivalirudin, or other agent) directly in support of PCI.
Približne 98 % pacientov (v každej liečebnej skupine) užívalo antitrombíny (heparín, heparín s nízkou molekulovou hmotnosťou, bivalirudín alebo inú látku) priamo na podporu PCI.
Approximately 9–17 % of patients treated with Taltz at the recommended dosing regimen developed anti-drug antibodies, the majority of which were low titres and not associated with reduced clinical response up to 60 weeks of treatment.
Približne u 9–17 % pacientov liečených Taltzom v odporúčanom dávkovacom režime sa vytvorili protilátky proti lieku, väčšina ktorých mala nízke titre a nesúviseli so zníženou klinickou odpoveďou do 60. týždňa liečby.
Approximately dose-linear pharmacokinetics were observed in healthy volunteers after single dose administration up to 250 micrograms/kg.
Farmakokinetika zhruba závislá od dávky sa pozorovala u zdravých dobrovoľníkov po jednej dávke do 250 mikrogramov /kg.
Approximately forty-eight percent of patients continued on stable doses of methotrexate (≤ 25 mg/week).
Približne štyridsaťosem percent pacientov pokračovalo na stabilnej dávke metotrexátu (≤ 25 mg/týždeň).
Approximately half of all patients had 3 or more organs involved in their disease and most patients had the lung (74 %), and/or lymph nodes (54 %) as a metastatic location for disease at baseline.
Približne polovica všetkých pacientov mala ochorením postihnuté 3 alebo viacej orgánov a väčšina pacientov mala pred začatím liečby metastázy ochorenia lokalizované v pľúcach (74 %) a/alebo v lymfatických uzlinách (54 %).
Approximately half of an oral dose of lesinurad is cleared via CYP2C9 metabolism.
Približne polovica perorálnej dávky lesinuradu je odbúraná metabolizmom sprostredkovaným CYP2C9.
Approximately half of infliximab-treated patients in clinical studies who were ANA negative at baseline developed a positive ANA during the study compared with approximately one fifth of placebo-treated patients.
V klinických štúdiách sa približne u polovice pacientov liečených infliximabom, ktorí mali pred začatím liečby negatívne ANA, vyvinula pozitivita ANA počas štúdie, v porovnaní s približne pätinou pacientov dostávajúcich placebo.
Approximately half of infliximab-treated patients in clinical studies who were ANA negative at baseline developed a positive ANA during the study compared with approximately one fifth of placebo-treated patients.
V klinických štúdiách sa približne u polovice pacientov liečených infliximabom, ktorí mali pred začatím liečby negatívne ANA, vyvinula pozitivita ANA počas štúdie, v porovnaní s približne pätinou pacientov liečených placebom.
Approximately half of the cattle were vaccinated with Bovela and the rest received a dummy injection.
Približne polovica hovädzieho dobytka bola zaočkovaná očkovacou látkou Bovela a zvyšné zvieratá dostali zdanlivú injekciu.
Approximately half of the diarrhoea episodes started within the first week of treatment.
Približne polovica epizód hnačky sa začala v prvom týždni liečby.
Approximately half of the dose is excreted in the urine and somewhat less in faeces.
Približne polovica dávky sa vylúči močom a o niečo menej stolicou.
Approximately half of the patients had at least 3 years of prior exposure to Viramune immediate-release prior to entering study 1100.1526.
Približne polovica pacientov mala pred vstupom do klinickej štúdie 1100.1526 minimálne 3 roky predchádzajúcu expozíciu Viramunu s okamžitým uvoľňovaním.
Approximately half of the patients in each group were male.
Približne polovica pacientov v každej skupine boli muži.
Approximately half of the patients in the weekly treatment group (15 of 32; 47%) had left ventricular hypertrophy at baseline, defined as LVM index 103 g/m2.
Približne polovica pacientov v skupine týždennej terapie (15 z 32; 47 %) mala hypertrofiu ľavej komory na začiatku štúdie, definovanej ako index LVM 103 g/m2.
Approximately half of the patients reported an improvement in the most bothersome symptoms complained at baseline by the patients (i.e. nocturia, frequency, decreased stream, urgency, terminal dribbling and incomplete emptying), as assessed by the ICS-male questionnaire.
Približne polovica pacientov hlásila zlepšenie najviac obťažujúcich príznakov udávaných na začiatku (tj. nočné močenie, frekvencia močenia, oslabenie prúdu pri močení, nutkanie na močenie, prerušované močenie a neúplné vyprázdňovanie), čo bolo vyhodnotené prostredníctvom ICS – male dotazníka.
Approximately half of the patients treated for more than 1 year were PASI 75 responders (when all dropouts were considered as non-responders).
Približne polovica pacientov, ktorí boli liečení viac ako 1 rok dosiahli PASI 75 (pri čom všetci vyradení pacienti boli považovaní za neodpovedajúcich na liečbu).
Approximately half of the patients treated with Myozyme in infantile-onset clinical studies and 28% of the patients treated with Myozyme in a late-onset clinical study developed infusion associated reactions (IARs).
Približne u polovice pacientov liečených liekom Myozyme v štúdiách u pacientov s nástupom ochorenia v ranom detstve a 28 % pacientov liečených Myozymom v klinickej štúdii s neskorým nástupom ochorenia sa vyvinuli reakcie súvisiace s infúziou (IAR-Infusion Associated Reactions).
Approximately half of the patients were ages 1 to 3 years.
Približne polovica pacientov bola vo veku 1 až 3 roky.
Approximately half of the patients who developed an ANC < 1 x 109/ l did so within 8 weeks after starting therapy.
Približne u polovice pacientov, u ktorých ANC klesol na < 1 x 109/l, došlo k tomuto poklesu v priebehu 8 týždňov po začatí liečby.
Approximately half of the patients who use Protopy have some type of skin irritation where they have applied the ointment.
Približne polovica pacientov, ktorí používajú Protopy má nejakým spôsobom podráždenú kožu
Approximately half of the patients who use Protopy have some type of skin irritation where they have applied the ointment.
Približne polovica pacientov, ktorí používajú Protopy má nejakým spôsobom podráždenú kožu na ošetrovanom mieste.
Approximately half of the study population had at least two of the cardiovascular history entry criteria.
Približne polovica populácie štúdie mala aspoň dve vstupné kritériá kardiovaskulárnej anamnézy.
Approximately half of the study population had at least two of the cardiovascular history entry criteria.
Približne polovica populácie štúdie spĺňala aspoň dve z kardiovaskulárnych vstupných kritérií.
Approximately half of the subjects treated with naltrexone / bupropion who experienced vomiting first reported the event during the dose escalation phase.
Približne polovica subjektov liečených naltrexónom / bupropiónom, u ktorých sa vyskytlo vracanie, nahlásila túto udalosť v priebehu fázy zvyšovania dávky.
Approximately half of the thrombotic events is localised in cerebral vessels.
Približne polovica trombotických príhod je lokalizovaná v mozgových cievach.
Approximately half the cases were lymphomas.
Približne polovica prípadov boli lymfómy.
Approximately half the cases were lymphomas.
Približne polovica týchto prípadov boli lymfómy.
Approximately half the cases were lymphomas.
Približne v polovici prípadov sa jednalo o lymfómy.
Approximately half the patients in each treatment group had ER-positive and/or PgR-positive disease.
Približne polovica pacientov v každej liečebnej skupine mala ochorenie s pozitivitou ER a/alebo s pozitivitu PgR.
Approximately half the patients in each treatment group had hormone receptor-positive disease (defined as ER positive and/or PgR positive).
Približne polovica pacientov v každej liečebnej skupine mala ochorenie s pozitivitou hormonálnych receptorov (definované ako ochorenie s pozitivitou ER a/alebo s pozitivitou PgR).
Approximately half the radioactivity administered orally as [14C]­netupitant was recovered from urine and faeces within 120 h of dosing.
Približne polovica rádioaktivity podanej perorálne ako [14C]­netupitant bola zistená z moču a stolice počas 120 hodín po podaní dávky.
Approximately linear pharmacokinetics is observed at steady state in the population pharmacokinetic studies.
Približne lineárna farmakokinetika sa pozorovala pri rovnovážnom stave v populačných farmakokinetických štúdiách.
Approximately one month after the toddler dose, the proportion of subjects in each group achieving this same antibody concentration threshold was >97%, except for serotype 3 (71% in preterm infants and 79% in term infants).
Približne 1 mesiac po posilňovacej dávke dosiahol podiel osôb v každej skupine tú istú hraničnú koncentráciu protilátok a bol > 97 %, okrem sérotypu 3 (71 % u predčasne narodených detí a 79 % u novorodencov narodených v normálnom termíne).
Approximately one third (Psoriasis Study 1) and one quarter (Psoriasis Study 2) of subjects had Psoriatic Arthritis (PsA).
Približne jedna tretina (v 1. štúdii psoriázy) a jedna štvrtina (v 2. štúdii psoriázy) subjektov mala psoriatickú artritídu (PsA).
Approximately one third of patients can be expected to experience adverse reactions following treatment with tenofovir disoproxil fumarate in combination with other antiretroviral agents.
Približne u jednej tretiny pacientov sa môže očakávať výskyt nežiaducich účinkov v dôsledku liečby tenofovir-dizoproxilfumarátom v kombinácii s inými antiretrovírusovými látkami.
Approximately one third of patients were receiving insulin in combination with metformin and/or a sulphonylurea.
Približne jedna tretina pacientov dostávala inzulín v kombinácii s metformínom a/alebo sulfonylureou.
Approximately one third of patients were receiving insulin in combination with metformin and/or a sulphonylurea.
Približne tretina pacientov dostávala inzulín v kombinácii s metformínom a/alebo sulfonylmočovinou.
Approximately one-half of the patients in MERLIN-TIMI 36 had a history of angina.
Približne polovica pacientov v štúdii MERLIN-TIMI 36 malo anamnézu angíny.
Approximately one-third of antibody-positive patients had antibodies with neutralising activity in vitro.
Približne u jednej tretiny pacientov s pozitívnymi protilátkami boli zistené in vitro neutralizujúce protilátky.
Approximately one-third of patients had failed prior TNF antagonist therapy.
Predchádzajúca liečba antagonistom TNF zlyhala u približne tretiny pacientov.
Approximately one-third of patients had not received prior phototherapy, conventional systemic or biologic therapy.
Približne jedna tretina pacientov nedostala predchádzajúcu fototerapiu, konvenčnú systémovú alebo biologickú terapiu.
Approximately one-third of telithromycin was eliminated unchanged; 20% in faeces and 12% in urine.
Približne jedna tretina telitromycínu sa vylúči nezmenená, 20% stolicou a 12% močom.
Approximately one-third of the patients enrolled (76 [33.8%] in the Ilaris group and 84 [36.7%] in the triamcinolone acetonide group) had documented inability (intolerance, contraindication or lack of response) to use both NSAIDs and colchicine.
Približne u jednej tretiny zaradených pacientov (76 [33,8 %] v skupine Ilarisu a 84 [36,7 %] v skupine triamcinolónacetonidu) bolo zdokumentované, že nemôžu (pre intoleranciu, kontraindikáciu alebo nedostatočnú odpoveď) používať NSAID ani kolchicín.
Approximately one-third of the patients in clinical studies who received sunitinib were 65 years of age or over.
Približne jedna tretina pacientov v klinických štúdiách, ktorá dostávala sunitinib, mala 65 rokov a viac.
Approximately three-quarters of the events began during the first week of treatment, and in most patients the events resolved without dosing interruption.
Približne tri štvrtiny týchto udalostí začali v prvom týždni liečby a u väčšiny pacientov odozneli bez prerušenia liečby.
Approximately twice the proportion of patients in the placebo group in the first 12 weeks of Studies HS-I and HS-II, compared with those in the Humira group experienced worsening of abscesses (23.0% vs 11.4%, respectively) and draining fistulas (30.0% vs 13.9%, respectively).
V prvých 12 týždňoch štúdií HS-I a HS-II približne dvakrát vyšší podiel pacientov v skupine s placebom v porovnaní s tými, ktorí boli v skupine liečenej Humirou, zaznamenal zhoršenie abscesov (23,0 % verzus 11,4 %) a vytekajúcich fistúl (30,0 % verzus 13,9 %).
Approximately two to three fold increases in clobazam and five fold increases in norclobazam plasma levels respectively have been reported with co-administration of stiripentol in children with Dravet’s syndrome.
Asi dvoj- až troj-násobné zvýšenia plazmatických hladín u klobazamu a päť-násobné zvýšenie u norklobazamu bolo hlásené pri spoločnom podávaní stiripentolu deťom s Dravetovým syndrómom.
Apr  Aug  Dec
Apríl  August  December
Apremilast administered at doses of up to 50 mg BID did not prolong the QT interval in healthy subjects.
Apremilast podávaný v dávkach až do 50 mg BID (dvakrát denne), nepredĺžil QT interval u zdravých jedincov.
Apremilast can be co-administered with a potent CYP3A4 inhibitor such as ketoconazole.
Apremilast môže byť súbežne podávaný so silným CYP3A4 inhibítorom ako je ketokonazol.
Apremilast can be co-administered with methotrexate.
Apremilast môže byť súbežne podávaný s metotrexátom.
Apremilast can be co-administered with oral contraceptives.
Apremilast môže byť súbežne podávaný s perorálnou antikoncepciou.
Apremilast did not induce mutations in an Ames assay or chromosome aberrations in cultured human peripheral blood lymphocytes in the presence or absence of metabolic activation.
Apremilast nevyvolával mutácie v Amesovom teste alebo chromozomálne aberácie v kultivovaných ľudských lymfocytoch z periférnej krvi s metabolickou aktiváciou alebo bez nej.
Apremilast exposure is decreased when administered concomitantly with strong inducers of CYP3A4 (e.g. rifampicin) and may result in reduced clinical response.
Expozícia apremilastu sa znižuje pri súbežnom podávaní so silnými induktormi CYP3A4 (napr. rifampicín) a môže mať za následok zníženie klinickej odpovede.
Apremilast has no influence on the ability to drive and use machines.
Apremilast nemá žiadny vplyv na schopnosť viesť vozidlá a obsluhovať stroje.
Apremilast is contraindicated during pregnancy.
Apremilast je kontraindikovaný počas gravidity.
Apremilast is not genotoxic.
Apremilast nie je genotoxický.
Apremilast is the major circulating component following oral administration.
Apremilast je hlavnou cirkulujúcou zložkou po perorálnom podaní.
Apremilast is well absorbed with an absolute oral bioavailability of approximately 73%, with peak plasma concentrations (Cmax) occurring at a median time (tmax) of approximately 2.5 hours.
Apremilast je dobre absorbovaný, s absolútnou perorálnou biologickou dostupnosťou približne 73 %, s maximálnou plazmatickou koncentráciou (Cmax) vyskytujúcou sa v mediáne času (tmax) približne 2,5 hodiny.
Apremilast pharmacokinetics are linear, with a dose-proportional increase in systemic exposure in the dose range of 10 to 100 mg daily.
Farmakokinetika apremilastu je lineárna, so zvýšením systémovej expozície úmerne k dávke v rozsahu dávok 10 až 100 mg denne.
Apremilast undergoes extensive metabolism with only 3% and 7% of the administered parent compound recovered in urine and faeces, respectively.
Apremilast prechádza rozsiahlou biotransformáciou s iba 3 % podanej materskej zlúčeniny vylúčenými v moči a 7 % vylúčenými v stolici.
Apremilast was detected in milk of lactating mice (see section 5.3).
Apremilast bol zistený v mlieku dojčiacich myší (pozri časť 5.3).
Apremilast was not clastogenic in an in vivo mouse micronucleus assay at doses up to 2000 mg/kg/day.
Apremilast nebol pri dávkach do 2 000 mg/kg/deň klastogénny v in vivo mikronukleárnom teste u myší.